-
Product Insights
NewLikelihood of Approval Analysis for Pulmonary Arterial Hypertension
Overview How likely is it that the drugs in Pulmonary Arterial Hypertension will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pulmonary Arterial Hypertension Overview Pulmonary arterial hypertension (PAH) is a type...
-
Product Insights
NewLikelihood of Approval Analysis for Occlusive Arterial Disease (OAD)
Overview How likely is it that the drugs in Occlusive Arterial Disease (OAD) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Occlusive Arterial Disease (OAD) Overview Occlusive arterial disease (OAD), also...
-
Product Insights
NewLikelihood of Approval Analysis for Peripheral Artery Occlusive Disease (PAOD)
Overview How likely is it that the drugs in Peripheral Artery Occlusive Disease (PAOD) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Peripheral Artery Occlusive Disease (PAOD) Overview Peripheral artery occlusive...
-
Product Insights
NewLikelihood of Approval Analysis for Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Overview How likely is it that the drugs in Coronary Artery Disease (CAD) (Ischemic Heart Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Coronary Artery Disease (CAD) (Ischemic Heart Disease)...
-
Sector Analysis
NewPeripheral Artery Disease (PAD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in PAD therapeutics. - More than 18,000,000 diagnosed prevalent cases of PAD are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for PAD. - The innovator marketed drugs space for PAD includes coagulation factor X inhibitors, fibrinogen activators, hepatocyte growth factor activators, and vascular endothelial growth factor activators, amongst others. - The PAD pipeline mainly includes receptor agonists, followed by biological factor activators...
-
Product Insights
NewLikelihood of Approval Analysis for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
Overview How likely is it that the drugs in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Peripheral Arterial Disease (PAD)/ Peripheral Vascular...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mitiperstat in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mitiperstat in Pulmonary Arterial Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mitiperstat in Pulmonary Arterial Hypertension Drug Details: Mitiperstat is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tacrolimus in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tacrolimus in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tacrolimus in Pulmonary Arterial Hypertension Drug Details: Tacrolimus (SPI-026) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Imatinib in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib in Pulmonary Arterial Hypertension Drug Details: Imatinib (AER-901) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Empagliflozin in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Empagliflozin in Pulmonary Arterial Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Empagliflozin in Pulmonary Arterial Hypertension Drug Details: Empagliflozin (Jardiance, BI...